Notice of Extraordinary General Meeting in Asker Healthcare Group AB (publ)
Asker Healthcare Group AB (publ), Reg. No. 559184-9848 (“Asker” or the “Company”), with its registered office in Danderyd, gives notice of the Extraordinary General Meeting to be held on 9 December 2025 at 09.00 CET at the premises of Advokatfirman Vinge at Smålandsgatan 20, SE-111 46 Stockholm, Sweden. Registration starts at 08.30 CET.
Right to participate in the Extraordinary General Meeting and notice of participation
Participation in the Extraordinary General Meeting at the venue
A shareholder who wishes to participate in the Extraordinary General Meeting at the venue, in person or represented by a proxy, must:
- be recorded as a shareholder in the share register maintained by Euroclear Sweden AB relating to the circumstances on 1 December 2025, and
- no later than 3 December 2025 give notice by post to Asker Healthcare Group AB (publ), c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden, via e-mail to [email protected], or by telephone +46 8 402 91 33. When providing such notice, the shareholder shall state name, personal or corporate registration number, address, telephone number and the number of any accompanying assistant(s) (maximum two assistants) as well as information about any proxy.
If a shareholder is represented by proxy, a written, dated proxy for the representative must be issued. A proxy form is available on the Company’s website, www.asker.com. If the proxy is issued by a legal entity, a certificate of registration or equivalent certificate of authority should be enclosed. To facilitate the registration at the Extraordinary General Meeting, the proxy and the certificate of registration or equivalent certificate of authority should be sent to the Company as set out above so that it is received no later than 8 December 2025.
Participation by voting in advance
A shareholder who wishes to participate in the Extraordinary General Meeting by voting in advance must (i) be recorded as a shareholder in the share register maintained by Euroclear Sweden AB relating to the circumstances on 1 December 2025, and (ii) give notice no later than 3 December 2025, by casting its advance vote in accordance with the instructions below so that the advance vote is received by the Company no later than on that day.
A shareholder who wishes to participate in the Extraordinary General Meeting at the venue in person or represented by a proxy must give notice thereof in accordance with what is set out under Participation in the Extraordinary General Meeting at the venue above. This means that a notification by advance vote is not sufficient for a person who wishes to participate at the venue.
A special form shall be used when advance voting. The advance voting form is available on the Company’s website www.asker.com. A completed and signed form may be submitted by post to Asker Healthcare Group AB (publ), c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden or via e-mail to [email protected]. The completed form shall be received by the Company not later than 3 December 2025. Shareholders who are natural persons may also cast their votes electronically through BankID verification via Euroclear Sweden AB’s website, https://www.euroclear.com/sweden/generalmeetings/. The shareholder may not provide special instructions or conditions in the voting form. If so, the vote (i.e. the advance vote in its entirety) is invalid. Further instructions and conditions are included in the form for advance voting.
If a shareholder votes by proxy, a written and dated proxy shall be enclosed to the advance voting form. A proxy form is available on the Company’s website www.asker.com. If the shareholder is a legal entity, a certificate of registration or equivalent certificate of authority should be enclosed. If a shareholder has voted in advance and then attends the Extraordinary General Meeting in person or through a proxy, the advance vote is still valid except to the extent the shareholder participates in a voting procedure at the Extraordinary General Meeting or otherwise withdraws its casted advance vote. If the shareholder chooses to participate in a voting at the Extraordinary General Meeting, the vote cast will replace the advance vote with regard to the relevant item on the agenda.
Nominee-registered shares
To be entitled to participate in the Extraordinary General Meeting, a shareholder whose shares are held in the name of a nominee must, in addition to providing notification of participation, register its shares in its own name so that the shareholder is recorded in the share register relating to the circumstances on 1 December 2025. Such registration may be temporary (so-called voting right registration) and is requested from the nominee in accordance with the nominee’s procedures and in such time in advance as the nominee determines. Voting right registrations completed by the nominee not later than 3 December 2025 are taken into account when preparing the share register.
Proposed agenda
- Opening of the Extraordinary General Meeting
- Election of chairperson of the Extraordinary General Meeting
- Preparation and approval of the voting list
- Approval of the agenda
- Election of one or two persons to approve the minutes
- Determination of whether the Extraordinary General Meeting has been duly convened
- Resolution on number of members of the Board of Directors
- Resolution on board fees
- Election of new member of the Board of Directors
- Closing of the Extraordinary General Meeting
Proposed resolutions
Election of chairperson of the Extraordinary General Meeting (item 2)
The Nomination Committee proposes that Amanda Knutsson, member of the Swedish Bar Association, from Advokatfirman Vinge, or in case she has an impediment, the person assigned by the Nomination Committee instead, is elected as chairperson of the Extraordinary General Meeting.
Resolution on number of members of the Board of Directors (item 7)
The Nomination Committee proposes that the Board of Directors shall continue to consist of six (6) board members.
Resolution on board fees (item 8)
At the Annual General Meeting on 4 March 2025, it was resolved that fees shall amount to SEK 800,000 to the chairman of the Board of Directors, SEK 390,000 to each independent member of the Board of Directors, SEK 160,000 to the chairman of the Audit Committee, SEK 85,000 to each independent member of the Audit Committee, SEK 100,000 to the chairman of the Remuneration Committee and SEK 60,000 to the independent member of the Remuneration Committee.
The Nomination Committee proposes that the above board and committee fees shall also be paid to the dependent board members, pro rata from and including the Extraordinary General Meeting to and including the Annual General Meeting 2026.
Provided that the Extraordinary General Meeting resolves in accordance with the proposal under item 9, all six (6) board members will thus receive board and committee fees.
Election of new member of the Board of Directors (item 9)
The Nomination Committee proposes that Karl Petersson is elected as new member of the Board of Directors for the period until the end of the next Annual General Meeting. Karl Petersson will replace board member Anders Nyman who has announced that he will resign from the Board of Directors in connection with the Extraordinary General Meeting.
Information about the proposed new member of the Board of directors
Karl Petersson
Born: 1984
Work experience and current assignment: M.Sc in Industrial Engineering & Management from Linköping University. Investment director at Interogo Long-term Equity Advisors since 2025. Prior experience include work as Investment Director at Nordic Capital and Associate at SEB Enskilda Corporate Finance and as a member of the Board of Directors of iLOQ, ProGlove and Unilabs.
Shareholding in Asker (own and related parties): 0
Independent in relation to the Company and the Company management: Yes
Independent in relation to major shareholders: No
Shareholders’ right to obtain information
The Board of Directors and the CEO shall, if requested by a shareholder and if the Board of Directors believes that it can be done without material harm to the Company, provide information regarding circumstances that may affect the assessment of a matter on the agenda.
Number of shares and votes
There are 383,036,497 shares outstanding in Asker, corresponding to 383,036,497 votes. As of the date of this notice, the Company holds no own shares.
Documentation
The proposal and motivated statement from the Nomination Committee are available on the Company’s website www.asker.com. Relevant documents pursuant to the Swedish Companies Act will be made available at the Company’s office at Svärdvägen 3A, SE-182 33 Danderyd, and at the Company’s website, www.asker.com, no later than three weeks before the Extraordinary General Meeting. Copies of the documents will be sent to shareholders who so request and who inform the Company of their postal address.
Processing of personal data
For information on how your personal data is processed, see the integrity policy that is available on Euroclear’s website https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. If you have questions regarding our processing of your personal data, you can contact us by emailing [email protected].
Danderyd, November 2025
Asker Healthcare Group AB (publ)
The Board of Directors
For further information, please contact:
Emma Rheborg, Head of Communication Asker Healthcare Group
Phone: +46 73 313 62 17
E-mail: [email protected]
Asker Healthcare Group is a partner to caregivers and patients across Europe providing medical products and solutions. We build and acquire leading companies that together support the healthcare system to improve patient outcomes, reduce total cost of care and ensure a fair and sustainable value chain. We are a European healthcare group that combines the entrepreneurial drive of strong local companies, with the abilities and collected knowledge of a large group – driving progress in the healthcare sector. The group has more than 4 500 employees in 19 countries and revenues amounting to SEK 16 billion.
The information was submitted for publication, through the agency of the contact person set out above, on
14 November 2025, at 8:31 a.m. CET.